← Diabetes Connections | Type 1 Diabetes
Diabetes Connections | Type 1 Diabetes
BONUS: Dexcom updates & news from ADA with CEO Jake Leach
00:31:35
Loading summary
Transcript47 lines
- [00:00]
A
Foreign. Diabetes Connections I am talking to Dexcom CEO Jake Leach. Lots of news from Dexcom as they presented new information this weekend at the annual ADA conference. We're covering that. Plus did you also know that Dexcom will stop making the G6 in less than a month? That they are developing a new product for hospitals? Why? Dexcom's talking about potassium and we take a look at their Customer Advisory Council report. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider. Welcome to a bonus episode of Diabetes Connections. I'm your host Stacey Sims. We aim to educate and inspire about diabetes with a focus on people who use insulin. And I told you we were gonna have some of these bonus episodes and I think that's gonna continue. A lot of news coming out of ADA that I want to make sure and cover and some partnerships and new information. Please make sure to subscribe to the podcast in whatever podcast app you are listening and that way you will never miss a show. It's the easiest way to have it brought to you. And I have been terrible about talking about this, but you can watch most of the bonus episodes that we're doing this year on YouTube. Every episode is on YouTube, but usually only the bonus episodes are full video so you can check that out as well if you prefer to watch or listen. I just want to be everywhere that podcasts are so it's really easy to find us. You can also always listen to the show on the main homepage. That's diabetes-connections.com and while you're there please check out our Events tab to learn more about the in person diabetes events that we do all year long. We're going to be in Chicago this Wednesday. We have a couple of seats left for that. We are full for our Boston event later in June. There's a wait list for that one. And we have two Moms Night out events this fall, Detroit and Seattle and a few more events to come this year. So check back under that events tab@diabetes-connections.com My usual quick disclosure about Dexcom. Dexcom does sponsor the podcast. You will hear their ads on our regular non bonus episodes and they do sponsor us at Mom's Night Owl. However, when it comes to interviews that is not sponsored at all. There is no agreement on what to ask. We don't put questions in advance. It is separate. But I know you're sick of hearing that if you're a longtime listener, but it's really important just to put it out every single time. And if you are New when we do this type of interview from a conference like ada, I get limited time. There was a lot I wanted to follow up on here. So we will circle back around with Dexcom in the weeks and months to come and as always, let me know what you want to hear more about. Here is my interview with Dexcom CEO Jake Leech. Jake Leech, thanks for joining me from ada. How is the conference going? Let's just start with what Dexcom is presenting and talking about there.
- [03:02]
B
Yeah, certainly. Well, first off, Stacey, great to see you, great to be here. Yeah, I always love our time together. So yeah, we're at ada, just got started a couple days ago and at this conference we have some really exciting news. First off, we have our Connect study that will be presenting the results later this afternoon. That is a study in people with type 2 diabetes that use other glucose lowering medications, not using, you know, not insulin. So GLP1, SGLT2s and then a portion of the folks in this study don't use anything, no medications. There are usually diet and exercise lifestyle to managed diabetes. And so it's a study large randomized controlled trial. The goal is to show the impact of CGM in this population, which hasn't been done in a randomized controlled trial of this size. It's been done through real world evidence. We have lots of evidence that shows how CGM impacts this group and the improvements that are driven by using cgm. But this study I think is going to be a cornerstone to further advancing access for people to CGM around the world. So at this point we now have a complete data set spanning all the way from type 1 diabetes through the different stages of type 2, the evidence needed to show the impact this product can have. So now at this point, all people with diabetes, we have the evidence that proves what CGM could do and the benefits. So very excited to release that. Later this afternoon we also had new news where we acquired a company called Nutrisense, which is a company that is based on nutritional coaching guided by CGM for users. And we've been working as a partnership together for quite a while. I've been really excited about what they've been able to drive in terms of outcomes and better metabolic health and so wanted them to be part of the Dexcom team. So we're just looking to close that acquisition here in the coming weeks and very excited about that. We've also got a whole new version of Stello that we're launching here at the show. We've got new people getting access to it. It's a whole new mobile app experience. We've talked about it before, but we're actually starting to have people use it outside of Dexcom.
- [04:59]
A
What is different about the Stello? The hardware is the same, Software's different.
- [05:03]
B
Yeah, software is very different. So this design is, you notice from the moment you open the app, it's a very design, forward looking app. It looks very, very different. It looks, it's more akin to some of the most loved mobile tech apps out there. You know, our partner Aura has done a really nice job in that kind of user interface. So ours, while not copying them, has a lot of similarities in terms of just the way we use colors and the design. So we kind of took a fresh look at the just designs aesthetics. But the other thing we did was we've put insights that are generated from the mobile app experience upfront in the way that we display. Because a lot of our users who are using Stello, the number one piece of feedback is I'm really, I love this real time data, but what does this mean? Right. We're trying to connect the dots for em and we found that sometimes the insights get a little hidden and so we put them right up front. It also has an AI coach built into it so you can ask it all kinds of questions like, how am I doing today? How does this glucose look? What should I have for? Like you can ask it all kinds. How do I lower my glucose right now? Like, what can I do? Like, I get that question actually all the time. People are like, my glucose is running kind of high, what should I do? And I'm like, well, go take a walk. Like there's a lot of things you can do and then it learns the individual and what works for them. So it's, it's a really exciting experience. We're pulling in more of the activity data, sleep data from partners and using that in the coach as well. So it's a great experience. Looking forward to getting in people's hands for clarification.
- [06:28]
A
And I think most of my listeners know this Stello is a product that is over the counter. It is for people who do not use insulin. Any plans to export that kind of software. And I've used Stello. It has, it already had when I used it last year, a really great knowledge base in there. You could ask it a lot of questions. It had a lot of really basic stuff about type 2 diabetes that I think people found very helpful. Any plans to give that to the type 1 or Lada community?
- [06:53]
B
Absolutely. Our goal is to transition all of that, you know, new design and new design thinking as well as features. We know there's a lot of overlap, particularly when it comes to nutrition. And you think about like carb counting. And right now the Stello, the new version of Stelo, you can take a picture or enter the food meal information into the app and it'll not only analyze it, but it'll also give you the macronutrients associated with it. So carbs, protein, fat, and it also gives it a meal score in terms of what we anticipate it'll do to your glucose. That could be really helpful for all of our users. Right. And so that's where we want to transition this same technology across the whole portfolio of products. So Stello is kind of our ground where we do introduction, we do some experimenting, we really like what we're seeing here. So we want to move it over to the whole portfolio.
- [07:44]
A
Okay. Tons of questions for you, focusing mostly on things you're not presenting at ADA. But really first on my calendar is July 1st. G6 ceases production.
- [07:56]
B
Yes.
- [07:57]
A
Can you talk about why it seems very soon. I know it's probably not if you look at the timeline of Dexcom, but nuts and bolts and why you're doing this for a product that, you know, Jake is beloved.
- [08:09]
B
Yes. You know, G6 has been an amazing product that we launched eight years ago. It has been a fantastic product. And we basically are at the point now where one, we've already done lifetime buys on a number of the materials that are in that product, so don't have any more raw materials to build G6S. That's part of it. The other part too is that I need to transition those manufacturing lines over to G7 so we can make enough sensors. The G7 manufacturing lines are much more efficient than G6 in terms of I can build more sensors in the same amount of space. And so we need to be able to transition so we can serve the growing number of users. We're also really proud of where G7 is in terms of product performance, reliability and its ability to meet users needs. And so we're real stable with that at this point in time. So we are. It's the right time to do this transition. So it's kind of like a combination of all those things. We still have some G6 out there in the market. Basically most of our users have already moved over to G7, particularly most of our pediatrics have already moved over. But we still have some folks using G6 that we wanted to transition over to G7. So we've got a number of folks that can contact us. We can help them get an educational sample of G7 so they give it a try before they switch over. I think that's always, that's been my most helpful when folks, they love their G6, right? But you know, you need to move to G7, so give one a try. And so that, I think that's a great way to get the educational experience before they move to Uber.
- [09:30]
A
If I remember in the past too, because we've, we've done this, I mean, since the podcast in 2015, we've done this a few times with G4, G5 in the past, there have been a few devices and partnerships that have lagged. Are there any devices, are there any pump systems that only operate on G6 internationally or in the United States? There aren't. Right?
- [09:48]
B
No, we just, there was one internationally, but we just moved over to G7. They just announced that. So we're, we're good across all systems. And in the United States, all of our pump partners are also compatible with the 15 day sensor as well. So both G7, 10 day and 15 day are compatible with all of the pumps.
- [10:05]
A
And forgive me, you know, we do this a lot rapid fire with my limited time I have with you. But with the G7 15 day not approved yet for pediatrics.
- [10:14]
B
No, it's not. It's only approved for adults. And that was really around. As we design the products, we want to make sure that a really significant number of sensors last all the way to the end to 15 days. And we know when you know, you put a sensor in, what really dictates how long it lasts isn't necessarily the physical sensor itself. It's the biology of where the sensor, you know, when it was inserted that we call it a wound site. But basically where that sensor is in the body is, you know, interacting with the sensor on the first day and throughout the whole wear time. And the. In pediatrics, we tend to see that the sensors don't last as long on average out to 15 days. So we really have said right now, based on where the technology is at, 10 day is the right product for pediatrics because we want to make sure that people always have the sensors they need and we don't want to be replacing their sensors all the time if they're trying to use a 15 day. Now, majority of pediatrics could get a Sensor to go 15 days. But the experience for my kid. Yeah, exactly. Right. There's totally. I mean, it's like. So you have that experience, right? You know, like 10 day is the right technology for pediatrics at this point in time. G8 will be 15 day for everybody. But we're also gonna do some unique things about making sure that people have the sensors they need, even if it doesn't last about to 15 days, which usually it's either tape falls off or the sensor probe is no longer able to sense glucose in the wound site. We did this customer advisory council which has been a really important part of listening to our customers. And one of the things that really has resonated with that group has been our kind of explanation of the other things that are going on that have impact sensor beyond just the sensor itself. And a lot of it has to do with the interaction with the body and biology. And that has really landed quite well. And so we cover some of that in the report that we just published for everyone to see in terms of the output of that council. But that is a big part to sensor survival.
- [12:06]
A
I do want to talk about the council. Let's put that aside just for a moment though. A quick question about the 15 day. Why does it have a 60 minute warmup?
- [12:14]
B
So basically in, in that 15 day algorithm for the extended survival, to make it work right, it needed an hour of warmup time. But we are working on 15 or 30 minute warmup for all sensors in the portfolio. So the goal would be to get back to a 30 minute warmup for that product. But one of the things that's really unique about Dexcom is you can put your sensor in an hour before you plan to change away from your old one. So you can overlap them like that. And it is a really powerful feature that you basically have no, no downtime. And so that's one of the things that many. It. Sometimes it takes a little bit of time for folks to understand that. I'd like people to understand that right up front. You can basically put that sensor in a little bit early and avoid any downtime. You just gotta remember the pairing code.
- [12:58]
A
You gotta remember which one. I mean you can. Yeah, I just remember giving Benny a bath years ago and having two pump sites and like, oh no, you know, he's four years old. Which is the old pump site, which is the new one, make an X on it. You've got a couple of things coming out that I haven't heard discussed in too much detail. I'd like to ask you about. I understand a hospital product is coming pretty soon. What is that? What does that mean?
- [13:22]
B
So it's our goal is to have the first continuous glucose Monitor approved for use in the inpatient setting. I don't know if that's surprising to some listeners, but there is actually no sensor, continuous sensor, that's been approved for use in the hospital for subcutaneous use in the United States. So our goal, there's such a need there. If you look at how many dysglycemia events happen in the hospital and it's, you know, a lot of people with diabetes, but also people without diabetes that have stress induced dysglycemia, usually hyperglycemia from, you know, major surgeries that glucose control. There's a lot of people who actually are put on insulin in the hospital that don't have diabetes, but they're trying to help the body. The physicians are trying to help the body manage that glucose level. They use finger sticks and lab tests. They don't use continuous glucose monitors. And so there's been this significant demand coming from that environment, from the anesthesiologists, from all of the physicians in the hospital for a better tool. And so we feel like our technology is really well suited for hospital use. And so we're working on getting a product approved that will be used in the inpatient setting. And the idea there is to basically guide the glucose management in the hospital whether you have diabetes or not. Guide it with CGM instead of intermittent finger sticks, which are. We all know the challenges with doing that.
- [14:38]
A
Yeah. Is this product basically a G7 or a G8 that you just have to test in a hospital setting, or is it something completely new?
- [14:46]
B
No, it's a G7 type of product. There's some different features that are designed around the hospital, but the hardware. And we'll move to G8 quickly. One of the things that, for the hospital that'd be important, just like for everywhere else, is this idea of multiple analytes being able to be sensed subcutaneously. There's quite a few that could be helpful. I mentioned one recently around a potassium sensor. Managing potassium levels is. Obviously, it's easier in the hospital because you have access to large, you know, volume. You could draw blood from the patient and run it on an analyzer. But it sure would be easier to have continuous measurement, particularly for people with kidney disease or cardiac disease, cardiovascular disease. So there's other ones too, that I think lactate would be another great one. And so that G8 platform will be important for the hospital product in the long run.
- [15:31]
A
Yeah, this is my very next question is why potassium? You've led right into it. But it seemed to me that when dexcom announced that the first analyte it might focus on and. Analyte. You know, I gotta tell you Jake, that was a word I had to look up. But as you listen, it is just the thing being measured. Yep. Some companies Abbott is gonna be is just got their ketone measurement, ketone CGM approved in Europe. They're gonna work on United States approval, but you're working on potassium. And this is a little bit more clear now as we're looking at hospital. But you mentioned lactate is the second one, not ketones. Talk to me about the analyte issue that's now in front of CGM companies.
- [16:10]
B
Just so I'm clear, when you say analyte issue, you mean, you know, choosing another analyte to sense. Is that the really?
- [16:16]
A
Yeah, this looks like the next frontier. So how do you decide what you're gonna measure? How do you decide what you're gonna promote that you can measure? Cause my assumption is that once you figure out how to measure, period, you can do all these things. You just gotta figure out how to get the readout to be accurate to the user or the doctor.
- [16:32]
B
Yeah, I think the number one thing that we're focused on is making sure we're meeting customer needs and enhancing and improving on that. And one of the things we recognize is there is still plenty of opportunity to make glucose sensing more reliable and more accurate. And I think we all have had experiences where the majority of the time sensors are fantastic, but sometimes they need to be calibrated, sometimes they're not as accurate as you want, somet sometimes they're not as reliable as you want. So G8 has a lot of technology built into it that's brand new that really focuses in on glucose reliability, but then the next. So that's why I wanna make sure we don't forget about glucose. There's still a lot to do there,
- [17:07]
A
but we're coming back to it. Don't worry, lots to talk about.
- [17:09]
B
But when we talk about additional analytes, again it's around this making sure that you have a clinical outcome for the user that you're trying to drive. Potassium is a very clear example of there is no at home test for potassium. You cannot give a finger stick and test potassium. You need a larger sample of blood. And I can go into like the details around hemolysis and why, but the main thing is there is no way to monitor this at home. And so patients have to go to a lab or a hospital to get that measured. And it can be deadly when it gets out of range. And a lot of people with type 2 diabetes suffer from other chronic diseases where potassium monitoring is very important and you know, it's kind of life or life and death situation. So we feel like that is a very clear unmet need that we want to do. Lactate is another ketone is one where I think there is value in ketone sensing. But I think there's a lot of work which we're doing to determine the right way to introduce it clinically. Like what are the right levels to alert at, how do you alert and what is the guidance given to the user. There's no actual kind of clinical data at this point in time that talks about, here's what you would do with a continuous ketone monitor. So I think, you know, when we think about priorities and what we're working on, further enhancing our capabilities in glucose is prior to number one for us. And as we look at the analytes, we have multiple ones in development well beyond just ketones.
- [18:23]
A
Interesting. I will tell you Jake and I know like you said, clinical stuff is different, but when you find yourself squeezing urine soaked cotton balls that have been in your son's diaper to figure out if there are ketones, a ketone monitor sounds dandy. It would be helpful, one of those things. I know a small population of people with diabetes, but man, those were the days. You've mentioned G8 a couple times. Let's talk about that. What is going to be different here? Can you give us the high spots?
- [18:49]
B
Sure, sure. So start off with. It's a brand new wearable. So it's in a familiar architecture, right. It has a sensor probe and a patch and then a little kind of sensing unit that's attached to it. But it's half the size of G7, so it is much smaller, it's thinner, it, it, the everything about it is smaller and it has to enable that. We have a whole new design of the electronics that are inside the G8 platform. So it's a smaller battery, it's a smaller electronics, it's more advanced electronics. It's going to improve on all the aspects, the size, the connectivity, the glucose sensing in particular. And in the glucose sensing side, some of this really exciting technology that we've been working on for many, many years is basically we've put another capability into the system to measure another signal from the sensor that allows us to adjust the sensor over time while you're wearing it. So the way that I describe it is it's like every so often you have a sensor that you feel maybe use our calibration feature and particularly those that are, you know, really after accuracy and they, they use that finger stick calibration. But it's, you know, it's, it's not easy, it's, you know, not particularly convenient to handle, have a finger stick meter and measure for calibration. So this system actually self adapts it from that other signal where you can measure the health of the sensor and over time. And that is one of the things that leads to this significant advancement in accuracy. And a big part of it is just pulling the outliers in because the G7 is the most accurate and with the 15 day longest lasting sensor out there. But there's still opportunities to improve it. And so we see that particularly the outlier sensors, this G8 system is going to help pull that in and make it even more accurate.
- [20:30]
A
I don't want to put words in your mouth, but let me then ask it this way. So if you're not doing a finger stick calibration, you know, a finger stick blood is incredibly accurate. If you're not doing that and then you're, you're relying on another substance that the dexcom is measuring, how accurate is that? Other. I know I'm not really understanding in other words, like why would that be more accurate or just as accurate as a finger stick.
- [20:56]
B
One thing I would say is the finger sticks are not that accurate. Like they're, they're within a range but you know, sometimes the sensor will be off and a finger stick is more accurate than the sensor. Right. In this situation, the G8 will be proven in clinical studies where we use reference blood analyzers to, you know, to show the performance. So the performance of this product is really incredible. It makes good sensors better, uh, is really the way I think about it. It is just gonna be a step change experience in terms of glucose.
- [21:24]
A
Well, we'll see those clinical trials too. I mean it'll be really fascinating.
- [21:27]
B
It will be. And when I think about aid user, I mean it's important for all of our users, even our Stell users. The number one reason people stop using a CGM today, whether it's Dexcom or a competitor's product, is because they don't feel the glucose data is reliable enough. That's the number one reason. And so that's why we're like the number one thing to do is to go after that.
- [21:45]
A
All right, let's talk about this advisory council. I guess my top question from it is this release and the reporting I've seen around it seems like it's a real Mea culpa in a way from dexcom. Like we heard you had complaints. We're listening. Here's what we're going to do. So rather than go through most of the report in the remaining time I have left, can you focus on the issues they identified? Goosenecking adhesive. Let's start with those two. What improvements is dexcom going to make here?
- [22:13]
B
So I think when around the sensor deployment issues that we kind of really ran into at the beginning of last year, that one was one that we identified clearly ourselves because we can see sensor performance. We saw that failure mode creeping up and we went and attacked it and learned a lot and really brought the reliability product, improved it. And now at this point in time, we're just below our historic levels for that failure mode, which is very, very low. And we actually, out of the work that we did there, we were going to drive it down to, I mean the goal is to get to zero out of box deployment failures. It's a pretty sophisticated system of deploying that sensor under the skin. And one of the challenges was one that we did run into was they didn't always get deployed on the skin. So you had this like loop on the sensor, which is why it was called a gooseneck. And that was a creative name. But, you know, we didn't want to see that. We don't, we never want to see that. So we attacked that. And that's one of the things that obviously everybody has talked about and was brought up, but some of the things, I think there were important learnings in there from the patients was really just around friction points. That was really where we were after understanding where are we adding burden to someone's life. With diabetes, our goal is always to reduce the burden. And you know, we always have the best intent. We always put the customer's intentions first. But sometimes when we actually implement it, particularly at scale now with the number of patients we serve, you know, we serve over three and a half million patients, people and that number continues to grow quite rapidly. And it's a very diverse group of people. We have systems that at this point in time, we're adding friction things around, you know, customer support, replacement sensors when needed. All of those things we learned quite a bit from the council around there, even just how messages were being interpreted. And some things were like our intent was not being interpreted properly. And so it's on us to correct that level of communication. We're also making enhancements to the devices. Communications connectivity is a big focus. We've made a lot of Enhancements, connectivity, patch, adhesion. So we've got a new patch that we're launching. So some of this was reaffirmed by the Advisory Council in terms of things we are already working on. And some of it is new work that was spawned based on our feedback from that council, which the important part of the council for me was I worked with the team to kick that off earlier this year as I became the CEO was I really wanted. I didn't want to just hear everyone tell us how great we were. I wanted to find out really where the friction points were and to get open and honest feedback around what we needed to do better. And so that was a big part of the council. So we, you know that. That it was a very diverse group of people on that council, and some of them were some of our more vocal critics, which was something I wanted to hear. I wanted to hear from everybody, and that was helpful for all of us.
- [24:48]
A
Okay. I don't know if anybody else is going to ask you about this, so I will. Of the 17 people on that council, I know four of them who take money from Dexcom. Kind of like how I take money from Dexcom. Right. We're very upfront about that. You guys have ads that run on the podcast. I always talk about disclosures. You and I did not talk about these questions ahead of time. You know, you're not editing what I say. But I also do take money in the form of sponsorship for Mom's Night Out. And there are at least four people on that list. I can look at that and say, yep, yep, yep. And while the report looks great. Right. The concerns seem to be the concern of the community. It's not disclosed anywhere. So first, can you disclose that at the next report? I think that's really important for credibility, not just for dexcom, but for those people who should have disclosed it themselves. And don't just. Why. Why'd you let people on the council are taking money? I think I was disappointed in that, Jake.
- [25:37]
B
Interesting. Okay, well, that's. That's good feedback. That's good to understand. I think the reason why we, you know, as we look at the makeup of that.
- [25:44]
A
I didn't even apply, like, why. Okay, go ahead. I'm sorry.
- [25:47]
B
Well, I think what I would say is the feedback that we got from them, I can guarantee you, is not influenced by our support of their programs. They are all actual users or family members of users have a lot of experience and have an outlet for them to talk about their experience. And I think if you look at the Folks, particularly even the ones on the council that we sponsor some of their work, they don't hold back punches. They tell it like it is. If you watch any of their content, they're definitely giving us raw feedback. And I think through the council we even, you know, we got even a little deeper into things. And so I think disclosure is a great point. Like we'll make sure that that's very, very clear. But I, I can guarantee you that did not impact we. Like I said, I didn't want people just to tell us how great we are. I wanted to hear about what we needed to do better.
- [26:33]
A
Now you're thinking, why did I let these people punch me in the face and I paid them?
- [26:38]
B
No, it's, it's. I mean, in the end we're all doing this for the same reason, which is to drive better care for people with diabetes.
- [26:44]
A
Well, I appreciate you answering that because I was just surprised to see that. I know we don't have a ton of time left. One thing I did forget to ask you about though was the Dexcom Flex. Yeah, what is that? I know it's only in Germany, right, But what is it?
- [26:57]
B
So basically outside the United States as well as inside the United States, there's, you know, we have different portfolio of products in the US we have G7 and Celo and it kind of covers this huge opportunity for helping people better manage their glucose, different patients. When you go outside the US we have a portfolio too and we have a product called Dexcom One Plus. It's not available here in the U.S. it's available outside the U.S. it's really for people who use insulin but don't use aid. And that's the majority of people that are on multiple daily injections. I think the stat's actually 94% of people in the world that are on MDI are using injections, not closed loop AIT systems. So Dexcom One plus is a product for that segment. In Germany too, there's G7 for all intensive insulin users, whether you're a type 1 or type 2. And we're starting to see access open up for basal insulin users. And so Those with type 2 using single injections per day long acting insulin. And that's Flex product is specifically designed for that population. And so like our feature like Smart Basil and some of the things that we're introducing here in the US on G7 that'll be built in to the Flex product. So it's really a product that's specifically for that population and we find that different healthcare Systems work differently. So that's why we have this portfolio outside the US in terms of making sure we've got the right product for the different profiles of patients.
- [28:11]
A
And then final question here, it leads me to think, do you see a time where or really where kind of sounds like with the connect study and other things we're already getting there. Where a Dexcom product, you might flip a switch within the software and say I'm a type 1 insulin. You know, I use insulin in this way, I'm on an automated system or I'm a person who uses a once weekly shot of basal insulin and then I'm on MDI or I take a once weekly shot of basal but I use a GLP1 the rest of the time and I don't take fast acting insulin. I mean all of these things are. It's fascinating to see how much it's changed and developed. Could we see Dexcom be that flexible?
- [28:47]
B
Yeah, that. I mean ultimately over time that's we want to get to. We're always trying to be the easiest to use least amount of friction and really derive meaningful value. And I think your point around this, you know, there's all these different options. It speaks to the power of CGM across such a large population. It. It can really drive a lot of benefit for a lot of people. And the different use cases, we want features that really speak to those users and we want to innovate for everybody, including I want to make sure this is extremely clear. Our Type 1 community is still extremely important to us and we're going to continue to innovate on our products for them. When I think about G8 and the accuracy and reliability and the size of that sensor, it is the absolute best sensor for that for our Type 1 community as well as our others. Because when you're driving an aid system, you want the most accurate, reliable sensor possible. And so that's why we think that's a really important feature. We're also doing some stuff with the Follow app here coming up soon. That's going to be a really exciting. It's a long requested feature around acknowledging alerts and making sure that the followers know that the action was taken by on the glucose alert that they receive by the user. So there's a bunch more coming but we're really committed to innovating for all users.
- [29:54]
A
Always. Well, there's always more to talk about but I really appreciate your time, Jake, especially at ada. I know how busy everything is there. So we'll talk again soon. But thanks for your time. And I hope the rest of the conference goes well.
- [30:06]
B
Thanks, Stacy. Great to catch up.
- [30:12]
A
We scale the surface of a lot of issues there. So I'm going to link up more information on not just the full Advisory Council report. You can see that and you can, you know, see who's on it for yourself. I think they did a great job with the report, but I think it was important to ask that question. So I'm building up the full thing. You can see that yourself. I'm also going to link up the investor report where they talk more about that hospital device, they talk about potassium, and I will link up the Connect study. I talked to Jake before that study was released so we couldn't do a deep dive into the results. That was for people with type 2 taking GLP1 medications. So I'll link that up as well. As I said, we will circle back and talk to Dexcom about a lot more of this. And please stay tuned for more bonus episodes and information from ada. Thanks to my editor John Buchenis from Audio Editing Solutions for working on the weekend to get this episode out. And congratulations on your daughters in engagement. Mazel tov. That is so exciting. Thanks for all you do, John. And thank you for listening. I'm Stacey Sims. I'll see you back here soon. Until then, be kind to yourself. Diabetes Connections is a production of Stacy Sims Media. All rights reserved. All wrongs avenged.